ArticleOncotarget2018

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression

Laura N Eadie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.